Localization of PKCη in cell membranes as a predictor for breast cancer response to treatment

Onkologie

Volumn 35, Issue 5, 2012, Pages 260-266

  Karp, Galia ^a   Abu Ghanem, Sara ^a   Novack, Victor ^b   Mermershtain, Wilmosh ^b   Ariad, Samuel ^b   Sion Vardy, Netta ^b   Livneh, Etta ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Apoptosis; Breast cancer; Neoadjuvant; PKCh; Predicting response to therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PROTEIN KINASE C EPSILON; PROTEIN KINASE C ETA;

ADULT; ADVANCED CANCER; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CELL MEMBRANE; CELL NUCLEUS; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOPLASM; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL MEMBRANE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PROTEIN KINASE C; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84859997896     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000338443     Document Type: Article

References (28)

1. Griner EM, Kazanietz MG: Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007;7:281-294.
2. Nishizuka Y: Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995; 9:484-496.
3. Newton AC: Protein kinase C: structure and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001;101: 2353-2364.
4. Newton AC: Regulation of protein kinase C. Curr Opin Cell Biol 1997;9:161-167.
5. Aonsworth PD, Winstanley JHR, Pearson JM, Bishop HM, Garrod DR: Protein Kinase C alpha expression in normal breast, ductal carcinoma and in situ and invasive ductal carcinoma. Eur J Cancer 2004;40:2269-2273.
6. Kerfoot C, Huang W, Rotenberg SA: Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C alpha. J Histochem Cytochem 2004;52:419-422.
7. Ali S, Al-Sukhun S, El-Rayes BF, Sarkar FH, Heilbrun LK, Philip PA: Protein kinase C isoenzymes are differentially expressed in human breast carcinomas. Life Sci 2009;84:766-771.
8. Lahn M, Köhler G, Sundell K, Su C, Li S, Paterson BM, et al.: Protein kinase C alpha expression in breast cancer and ovarian cancer. Oncology 2006;67:1-10.
9. Pan Q, Bao LW, Kleer CG, Sabel MS, Griffith KA, Teknos TN, et al: Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res 2005; 65:8366-8371.
10. Masso-Welch PA, Winston JS, Edge S, Darcy KM, Asch H, Vaughan MM, et al.: Altered expression and localization of PKCeta in human breast tumors. Breast Cancer Res and Treat 2001;68:211-223.
11. Beck J, Bohnet B, Brugger D, Bader P, Dietl J, Scheper RJ, et al.: Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKCeta with MDR1, MRP and LRP gene expression. Brit J Cancer 1998;77:87-91.
12. Beck JF, Bohnet B, Brugger B, Dietel J, Scheper RJ: Expression analysis of protein kinase C isoenzymes and multidrug resistance associated genes in ovarian cancer cells. Anticancer Res 1998;18:701-705.
13. Beck JF, Handgretinger R, Klingebiel T, Dopfer R, Schaich M, Ehninger G: Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia 1996;10:426-433.
14. Akkaraju GR, Basu A: Overexpression of protein kinase C-h attenuates caspase activation and tumor necrosis factor a-induced cell death. Biochem Biophys Res Commun 2000;279:103-107.
15. Basu A: The involvement of novel protein kinase C isoenzymes in influencing sensitivity of breast cancer MCF-7 cells to tumor necrosis factor-alpha. Mol Pharmacol 1998;53:105-111.
16. Hussaini IM, Karns LR, Vinton G, Carpenter JE, Redpath GT, Sando JJ, et al.: Phorbol 12-myristate 13-acetate induces protein kinase Ceta-specific proliferative response in astrocytic tumor cells. J Biol Chem 2000;275:22348-22354.
17. Hussaini IM, Carpenter JE, Redpath GT, Sando JJ, Shaffrey ME, VandenBerg SR: Protein kinase C-eta regulates resistance to UV and gamma-irradiationinduced apoptosis in glioblastoma cells by preventing caspase-9 activation. Neuro Oncol 2002;4:9-21.
18. Matsumura M, Tanaka N, Kuroli T, Ichihashi M, Ohba M: The eta isoform of protein kinase C inhibits UV-induced activation of caspase 3 in normal human keratinocytes. Biochem Biophys Res Commun 2003;303:350-356.
19. Sonnemann J, Gekeler V, Sagrauske A, Muller C, Hofmann HP, Beck JF: Down-regulation of PKCeta potentiates the cytotoxic effects of exogenous tumor necrosis factor-related apoptosis-inducing ligand in PC-3 prostate cancer cells. Mol Cancer Ther 2004;3:773-781.
20. Rotem-Dai N, Oberkovitz G, Abu-Ghanem S, Livneh E: PKCeta confers protection against apoptosis by inhibiting the pro-apoptotic JNK activity in MCF-7 cells. Exp Cell Res 2009;315:2616-2623.
21. Abu-Ghanem S, Oberkovitz G, Benharroch D, Gopas J, Livneh E: PKCeta expression contributes to the resistance of Hodgkin's lymphoma cell lines to apoptosis. Cancer Biol Ther 2007;6:1375-1380.
22. Tamarkin A, Zurgil U, Braiman A, Hai N, Krasnitsky E, Maissel A, et al.: DNA damage targets PKCh to the nuclear membrane via its C1B domain. Exp Cell Res 2011;10:1465-1475.
23. Bacher N, Zisman Y, Berent E, Livneh E: Isolation and characterization of PKC-L, a new member of the protein kinase C-related gene family specifically expressed in lung, skin, and heart. Mol Cell Biol 1991;11:126-133.
24. Maissel A, Marom M, Shtutman M, Shahaf G, Livneh E: PKCeta is localizes in the Golgi, ER and nuclear envelope and translocates to the nuclear envelope upon PMA activation and serum-starvation: C1b domain and the pseudosubstrate containing fragment target PKCeta to the Golgi and the nuclear envelope. Cell Signal 2006;18:1127-1139.
25. Shtutman M, Hershko T, Maissel A, Fima E, Livneh E: PKCeta associates with cyclin E/Cdk2 complex in serum-starved MCF-7 and NIH-3T3 cells. Exp Cell Res 2003;286:22-29.
26. Sonnemann J, Gekeler V, Ahlbresht K, Brischwein K, Liu C, Bader P, et al.: Down-regulation of protein kinase Ceta by antisense oligonucletides sensitises A549 lung cancer cells to vincristine and paclitaxel. Cancer Lett 2004;209:177-185.
27. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ: Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 1998;18:790-798.
28. Weinstein-Oppenheimer CR, Henriquez-Roldan CF, Davis JM, Navolanic PM, Saleh OA, Steelman LS, et al.: Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 2001;7:2898-2907.